Drug intelligence / Profile preview

SWIVAX-MH

Development stage: Unknown
Lead developer: Indian Immunologicals
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

SWIVAX-MH is an inactivated bacterial vaccine designed for the active immunization of swine against Enzootic Pneumonia caused by *Mycoplasma hyopneumoniae*. Developed by Indian Immunologicals Limited, the vaccine contains inactivated whole-cell cultures of *M. hyopneumoniae* formulated with an adjuvant to enhance the immune response. It is primarily indicated for administration to piglets to reduce the severity of lung lesions and clinical signs associated with respiratory infections, which are major contributors to economic losses in the swine industry. The vaccine stimulates the production of specific antibodies and cell-mediated immunity to provide protection during the growing-finishing period.

Brand names: SWIVAX-MH
Other names: Mycoplasma hyopneumoniae vaccine

Beyond the preview

Go deeper on SWIVAX-MH.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SWIVAX-MH.

Explore the full profile